340B In The Spotlight – Key Program Developments

Polsinelli

In this issue, Polsinelli’s 340B and Reimbursement teams provide an update on the most recent developments in the ongoing 340B /Part B Payment litigation and also highlight recent Government Accountability Office (“GAO”) interest in covered entities duplicate discount prevention efforts. Below is a recap of both developments and practical guidance related to both issues as well as a reminder to submit comments to CMS’s recent hospital co-location guidance: 

Hospital 340B Entities Secure a Partial Victory in 340B / Part B Payment Litigation

Last week, hospital covered entities secured another partial victory in the ongoing litigation with the Centers for Medicare and Medicaid Services (“CMS”) over recent payment cuts to 340B drugs, but it is clear there may be a long road ahead. The D.C. District Court sided with hospitals by holding that the 2019 OPPS Final Rule’s reimbursement cut to Part B 340B drugs was unlawful. Building on its prior opinion declaring the 2018 OPPS 340B reimbursement reductions unlawful, the Court held that the Secretary of the U.S. Department of Health and Human Services (“HHS”) had again overstepped his authority when HHS made changes to the reimbursement methodology for separately payable 340B drugs. 

As a reminder, CMS slashed reimbursement for 340B drugs by nearly 30% from Average Sales Price (“ASP”) plus 6%, to ASP minus 22.5%. This continues to have tremendous financial consequences for many safety net hospitals, many of whom continue to lose millions in much needed reimbursement.

Please be aware that this was only a partial victory for covered entities. While the Court imposed an injunction, it refused to vacate the rules and instead, it sent the issue back to HHS to resolve. The Court reasoned that unresolved legal issues surrounding budget neutrality and retroactively increasing the 2018 and 2019 340B rates cautioned against a judicially prescribed remedy at this time (i.e., the Court refused to just set aside the OPPS rules).  

The Court remanded the issue to HHS to determine the least disruptive way to unwind this mess and address the 2018 and 2019 underpayments. Pursuant to the Court’s order, HHS must submit a status report on the agency’s progress in resolving the issue on or before August 5, 2019. Importantly, the Court noted that it retains jurisdiction over this matter and may reconsider the remedy if the HHS fails to fulfill its responsibilities in a prompt manner. The Plaintiffs have since filed a motion for a more definitive schedule that aligns with HHS’s OPPS rulemaking process whereby HHS typically releases a proposed rule in July and a final rule in November. 

Key takeaways for impacted covered entities:

  • Continue to report modifiers and expect ASPminus 22.5% reimbursement (when applicable) until HHS or the Court resolves these issues.
  • Be prepared to comment on proposed rules concerning remedies or additional payment cuts.
  • Expect this saga to continue for quite some time. HHS appealed the Court’s initial ruling and will likely appeal the Court’s most recent ruling because the Court’s opinion could have widespread implications on HHS’s rulemaking authority, so expect protracted appeals.
  • Providers should preserve their right to payments on individual Part B claims by filing appeals with their Medicare Administrative Contractors (MACs). We are aware that several MACs have published formal statements indicating that they will deny 340B appeals. Please note that covered entities may still appeal in order to reach later and more effective stages in the appeal process.
  • HHS is clearly dissatisfied with this ruling, and we anticipate recoupment of underpayments may be challenging, so implementing an effective claims appeal strategy is imperative.


GAO Interviews Covered Entities Regarding Duplicate Discount Prevention 

Covered Entities beware - the U.S. GAO is conducting interviews to assess covered entity efforts to prevent duplicate discounts in the Medicaid Drug Rebate and 340B Drug Pricing Programs.  Now is the time to prepare even if you did not receive the GAO’s interview request as duplicate discount prevention will continue to be a hot topic for the foreseeable future.
Drug manufacturers are pushing covered entities and states more aggressively to identify and resolve duplicate discounts in the Medicaid managed care (MCO) space, and the GAO’s exercise is a clear indicator that the topic is a very high priority in D.C. CMS and the Health Resources and Services Administration (“HRSA”) both have signaled that they expect drug manufacturers, covered entities and state Medicaid agencies to work together to formulate a method to prevent duplicate discounts in the MCO environment. HRSA has gone as far as saying they intend to issue guidance. To-date, that guidance does not exist, so stakeholders continue to pursue different strategies, and we believe the GAO’s exercise is intended to gather data on how to best ensure consistency.
As a best practice, covered entity 340B teams and leadership should have a detailed response strategy and talking points prepared if called to provide testimony or participate in informal discussions with government agencies or committees such as the GAO. In this instance, covered entities should evaluate:
  • Current legal, regulatory and policy expectations regarding duplicate discounts.
  • Current performance in meeting such expectations, and any challenges they have encountered in preventing duplicate discounts.
  • Whether those challenges are related to implementing state or internal requirements or procedures for preventing 340B duplicate discounts, internal compliance efforts, or governmental guidance or lack thereof.
The GAO is speaking to covered entities to learn more about their policies and methods for identifying 340B drugs provided to Medicaid fee-for-service and managed care (MCO) beneficiaries in order to prevent duplicate discounts. The GAO has sent a list of questions to covered entities to help guide the discussions, and the list clearly demonstrates where the GAO is headed.
The questions focus on 1) background of a covered entity’s participation in the program, 2) state policy on use of 340B for Medicaid patients, 3) covered entity policy on use of 340B for Medicaid patients, 4) 340B program compliance, and 5) working with stakeholders.
Below is a brief overview of information that GAO is seeking to gather. The topics are extremely broad, so covered entities should prepare very targeted responses.
1.  Background
GAO requests that covered entities provide a brief overview of the entity, including information about its 340B program participation. Some of the key background facts that GAO is seeking to gather include the length of 340B program participation, the number of child sites the entity has, the number of in-house pharmacies the entity has, whether the entity uses contract pharmacies to distribute 340B drugs and the number of contract pharmacies, and the number of Medicaid managed care plans with which the entity participates.
2.  State Policy on use of 340B for Medicaid Patients
GAO requests that entities describe their state’s policy related to 340B drugs. Specifically, GAO requests that covered entities describe whether, under their state’s policy, they can or must use 340B drugs for Medicaid fee-for-service patients and how that policy relates to drugs dispensed by the covered entity’s in-house pharmacy, drugs dispensed by contract pharmacies, and provider administered drugs. Further, GAO asks covered entities to describe any instructions the state provides entities on how they are to identify 340B drugs provided to Medicaid fee-for-service patients so they can exclude them for rebates and how those instructions may differ among dispensing methods. GAO requests similar information related to the covered entity’s state policy regarding the use of 340B drugs for Medicaid managed care patients.
3.  Covered Entity Policy on Use of 340B for Medicaid patients
GAO is looking for information on how covered entities implement their own policies to identify and reduce duplicate discounts in the 340B Program. GAO requests information on whether covered entities carve-in or carve-out 340B drugs for Medicaid fee-for-service and Medicaid managed care patients and the policy for drugs dispensed by in-house pharmacies, drugs dispensed by contract pharmacies, and provider-administered drugs. GAO also asks whether all of an entity’s child sites follow the same practice for carving in or carving out.
GAO also requests information related to how an entity that carves in 340B drugs for Medicaid patients identifies which drugs provided to Medicaid patients are 340B (for example, claims-level identifiers or provider-level identifiers), and how the method varies based on whether the patient is fee-for-service or managed care and the dispensing method of the drug. The GAO is seeking information related to challenges covered entities have encountered with any of these methods. GAO also requests information on how entities that carve out 340B drugs for Medicaid patients identify which patients are covered by Medicaid and should not be provided with 340B drugs, differences in identifying patients in fee-for-service vs. managed care, differences if the patient is receiving drugs at the covered entity vs. a contract pharmacy, and any challenges experienced in determining if a patient is enrolled in Medicaid.
4.  340B Program Compliance
GAO is also seeking information related to covered entity compliance activities, including audits. GAO asks covered entities to describe any oversight activities related to the prohibition on duplicate discounts, like self-audits or independent audits, and whether the entity has identified any instances of potential duplicate discounts through such oversight and any corrective action(s) taken to address such issues. GAO also asks covered entities to describe any challenges the entity faces in preventing duplicate discounts and any other concerns related to the occurrence of duplicate discounts.
5.  Working with Stakeholders
Lastly, GAO asks covered entities to describe how they work with various stakeholders, including state Medicaid agencies, drug manufacturers, and HRSA, with regard to 340B duplicate discounts. GAO asks covered entities to describe the extent which they communicate with state Medicaid agencies concerning 340B duplicate discounts, including reasons for contact and outcomes of such discussions. GAO also seeks information related to any manufacturer inquiries or audits related to suspicions of duplicate discounts as well as whether the covered entity has been the subject of a HRSA audit and findings of such audits. GAO also asks covered entities to address the sufficiency of guidance related to preventing duplicate discounts and whether any additional guidance from state Medicaid agencies, HRSA, and/or CMS would be beneficial. 
Key takeaways:
  • Prepare – Covered entities, whether they received the GAO interview request or not, should take the opportunity to document and refine responses to the GAO’s questions. Going through this exercise, involving your public policy, legal and compliance teams, and developing a talking points document will pay dividends down the road and will likely reduce anxiety if asked to participate in a probing exercise.
  • Focus on what you do best – Preventing duplicate discounts is challenging given the number of parties involved and the lack of consistent regulations.
  • Engage legal and compliance – Use the necessary resources to confirm actual and binding legal requirements regarding duplicate discounts, particularly in the MCO space. Don’t wait until asked by a manufacturer or an agency, and don’t rely on what others do.


Comments Due July 2, 2019 – CMS Provider-Based / Co-Location Guidance

Please consider submitting comments to CMS’s recent co-location guidance discussed here (https://www.polsinelli.com/intelligence/ealert-space-sharing-reboot). CMS’s guidance documents and interpretations will continue to play a key role in 340B child site strategies, so provider feedback is critical.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Polsinelli | Attorney Advertising

Written by:

Polsinelli
Contact
more
less

Polsinelli on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.